APEX is the first to launch and dose a take-home microdose psilocybin clinical trial, with the largest of its kind approved and beginning recruitment Q2 2023.
2
8-Year Data Exclusivity
Following commercial approval, APEX drug assets have data protection for 8 years in Canada.
3
Optimized Dosing Options and Clinical Pipeline
Two drug assets in the pipeline have the potential to be optimized for severity across indications.
4
Unmatched Team
Decades of healthcare, clinical and pharmaceutical experience with representation from the Veteran community in the C-suite and past corporate experience with Johnson & Johnson, Roche, GSK, Lilly, McKesson, Tilay, Sharp, and Canaccord.
Revenue Model
1
Pre-DIN SAP Macro-Dose
In clinic macro-dose with assisted psychotherapy through strategic partnerships utilizing Veteran focused clinics with Nationwide footprints. Pre-Drug Identification Number (DIN) revenue created by sales and insurance coverage for Canadian Armed Forces and RCMP Veterans.
2
DIN
Secure DIN by successful statistically powered clinical program for APEX-52 take-home microdose drug asset and APEX-90 macro-dose drug asset achieving regulatory approval in Canada, USA, Europe and Australia for broad commercial sales. Canadian Armed Forces and RCMP Veteran insurance programs from SAP macro-dose initiative to inform broader reimbursement.
